Contribution of pharmaceutical innovation to longevity growth in Germany and France, 20017

PharmacoEconomics

Volumn 30, Issue 3, 2012, Pages 197-211

  Lichtenberg, Frank R ^a,b  

^a Howard Hughes Medical Institute   (United States)

^b NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

Author keywords

Drug utilisation; Health policy; Mortality; Research and development.

Indexed keywords

PRESCRIPTION DRUG;

CANCER MORTALITY; FRANCE; GERMANY; HUMAN; LIFE EXPECTANCY; LONGEVITY; PHARMACEUTICAL CARE; PHARMACEUTICAL INNOVATION; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; STATISTICAL MODEL;

ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; DRUG INDUSTRY; FRANCE; GERMANY; HUMANS; LIFE EXPECTANCY; LONGEVITY; LONGITUDINAL STUDIES; NEOPLASMS; PRESCRIPTION DRUGS;

EID: 84857325272     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11587150-000000000-00000     Document Type: Review

References (39)

1. Nordhaus WD. The health of nations: the contribution of improved health to living standards. In: Murphy KM, Topel RH, editors. Measuring the gains from medical research: an economic approach. Chicago (IL): University of Chicago Press, 2003: 9-40
2. Murphy KM, Topel RH. The value of health and longevity. J Polit Econ 2006 Aug; 114 (5): 871-904 (Pubitemid 44734045)
3. Wikipedia. Human development index [online]. Available from URL: http://en.wikipedia.org/wiki/Human-Develop ment-Index [Accessed 2011 Oct 29]
4. Solow RM. A contribution to the theory of economic growth. Quart J Econ 1956; 70 (1): 65-94
5. Solow RM. Technical change and the aggregate production function. Rev Econ Stat 1957; 39 (3): 312-20
6. Romer P. Endogenous technological change. J Polit Econ 1990 Oct; 98 (5 Pt 2): S71-102
7. Jones C. Introduction to economic growth. New York: Norton, 1998
8. Solow RM. Investment and technological progress. In: Arrow K, Karlin S, Suppes P, editors. Mathematical methods in social sciences 1959. Stanford (CA): Stanford University Press, 1960: 89-104
9. Grossman GM, Helpman E. Innovation and growth in the global economy. Cambridge (MA): MIT Press, 1993
10. Bresnahan TF, Gordon RJ. The economics of new goods. Chicago (IL): University of Chicago Press, 1996
11. Bils M. Measuring the growth from better and better goods [NBER working paper no. 10606]. 2004 Jul [online]. Available from URL: http://www.nber.org/ papers/w10606 [Accessed 2011 Oct 29]
12. Hercowitz Z. The 'embodiment' controversy: a review essay. J Monetary Econ 1998; 41: 217-24 (Pubitemid 128178363)
13. Wikipedia. Exogenous growth model [online]. Available from URL: http://en.wikipedia.org/wiki/Exogenous-growth- model [Accessed 2011 Oct 29]
14. Bahk BH, Gort M. Decomposing learning by doing in new plants. J Polit Econ 1993; 101 (4): 561-83
15. Hulten CR. Growth accounting when technical change is embodied in capital. Am Econ Rev 1992 Sep; 82 (4): 964-80
16. Sakellaris P, Wilson DJ. Quantifying embodied technological change. Rev Econ Dyn 2004; 7 (1): 1-26 (Pubitemid 38074277)
17. National Science Foundation. US corporate R and D. Volume 1: top 500 firms in R and D by industry category [online]. Available from URL: http://www.nsf.gov/statistics/ nsf00301/expendit.htm [Accessed 2011 Oct 29]
18. IMS. IMS national prescription analysis database [inGerman; online]. Available from URL: http://www.imshealth.de/ sixcms/detail.php/375 [Accessed 2011 Oct 29]
19. US Food and Drug Administration. Drugs@FDA data files [online]. Available from URL: http://www.fda.gov/Drugs/ InformationOnDrugs/ucm079750.htm [Accessed 2011 Oct 29]
20. Gesundheitsberichterstattung des Bundes. The information system of the Federal Health Monitoring [in German; on- line]. Available from URL: http://www.gbe-bund.de/ [Accessed 2011 Oct 29]
21. Robert Koch Institute [in German; online]. Available from URL: http://www.gbe-bund.de/oowa921-install/servlet/oowa/ aw92/dboowasys921.xwdevkit/ xwd-init?gbe.isgbetol/xs-start- neu/&p-aid=i&p-aid=94387221&nummer= 179&p-sprache =E&p-indsp=-&p-aid=81869878 [Accessed 2011 Oct 29]
22. Gesundheitsberichterstattung des Bundes. The information system of the Federal Health Monitoring [in German; on- line]. Available from URL: http://www.gbe-bund.de/ [Accessed 2011 Oct 29]
23. Uchida E, Araki S, Murata K. Socioeconomic factors affecting the longevity of the Japanese population: a study for 1980 and 1985. J Biosoc Sci 1992; 24: 497-504
24. Hupfeld S. Non-monotonicity in the longevity-income relationship. J Pop Econ 2011; 24 (1): 191-211
25. Ruhm CJ. Macroeconomic conditions, health and mortality [NBER working paper no. 11007]. 2004 Dec [online]. Available from URL: http://www.nber.org/ papers/w11007 [Accessed 2011 Oct 29]
26. Lichtenberg FR. The quality of medical care, behavioral risk factors, and longevity growth. Int J Health Care Finance Econ 2011; 11 (1): 1-34
27. OECD. OECD health data 2011 [online]. Available from URL: http://www.oecd.org/document/30/0,3746,en-2649-37407- 12968734-1-1-1-37407,00. html [Accessed 2011 Oct 30]
28. Tufts Medical Center, Institute for Clinical Research and Health Policy Studies, The Center for Evaluation of Value and Risk in Health. Cost-Effectiveness Analysis Registry [online]. Available from URL: https://research.tuftsnemc.org/cear4/ [Accessed 2011 Oct 29]
29. Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 2003; 21 (7): 1404-11 (Pubitemid 46606423)
30. National Institute for Health and Clinical Excellence. The clinical effectiveness and cost-effectiveness of new drug treatments for rheumatoid arthritis: etanercept and infliximab. London: NICE, 2001 [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/RAAssessmentReport.pdf [Accessed 2011 Oct 29]
31. Lichtenberg FR. Have newer cardiovascular drugs reduced hospitalization? Evidence from longitudinal country-level data on 20 OECD countries, 1995-2003. Health Econ 2009; 18 (5): 519-34
32. Instituto Superiore di Sanita. EUROCARE databases [online]. Available from URL: http://www.eurocare.it/Home/tabid/36/Default.aspx [Accessed 2011 Oct 29]
33. Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer? JAMA 2000; 283 (22): 2975-8 (Pubitemid 30414510)
34. European Cancer Observatory. Table of cancer incidence and mortality rates [online]. Available from URL: http://eu-cancer.iarc.fr/16-table.html.en [Accessed 2011 Oct 29]
35. Lichtenberg FR. Has medical innovation reduced cancer mortality? [NBER working paper no. 15880]. 2010 Apr [online]. Available from URL: http://www.nber.org/papers/ w15880 [Accessed 2011 Oct 29]
36. IMS [online]. Available from URL: http://ims-america.com/portal/site/ imshealth/menuitem.a46c6d4df3db4b3d88f611 019418c22a/?vgnextoid= 1314e69040fb2210VgnVCM100 000ed152ca2RCRD&cpsextcurrchannel=1 [Accessed 2011 Oct 30]
37. CépiDC, INSERM. Examination of data on causes of death from 1979 to 2009 [in French; online]. Available from URL: http://www.cepidc.vesinet. inserm.fr/inserm/html/ index2.htm [Accessed 2011 Oct 29]
38. Eurostat. Causes of death: standardised death rate (per 100,000 inhabitants) (annual data) [online]. Available from URL: http://appsso.eurostat. ec.europa.eu/nui/show.do? dataset=hlth-cd-asdr&lang=en [Accessed 2011 Oct 31]
39. GERS [in French; online]. Available from URL: http://www.gie-gers.fr/ index.php3 [Accessed 2011 Oct 29]